trial

Perception of Facial Emotions in Schizophrenia and 22q11 Deletion Syndrome

NCTId NCT02634671
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
— · Completed
Enrollment 70 (actual)
Sponsored by Hôpital le Vinatier
Primary completion 2017-10-20
Synthesized from structured facts only — each point cited above.

Design & status

Phase
—
Status
Completed
Enrollment
70 (actual)
Study type
Interventional
Allocation
Non Randomized
Model
Parallel
Masking
None
Start
2015-11
Primary completion
2017-10-20
Eligibility
ALL · 15 Years · 50 Years

Interventions & indications

Drugs
schizophreniathe 22q11 deletion syndrome

Sponsors

Hôpital le VinatierLead Sponsor

Investigators

1
DEMILY CAROLINE, PHPrincipal Investigator

Sites

0 total

Facts & assertions

4 sourced
Enrollment
70
Phase
NA
Primary Completion Date
2017-10-20
Status
COMPLETED
relationships
The graph out of here
drug
schizophrenia
drug
the 22q11 deletion syndrome
drug
lead_sponsor
Hôpital le Vinatier
company
indication
Schizophrenia
indication
Schizophrenia
indication
investigator
DEMILY CAROLINE, PH
person